Gossamer Bio, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Gossamer Bio, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q3 2024.
Gossamer Bio, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$33.9M, a 16.2% increase year-over-year.
Gossamer Bio, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$72.8M, a 61.5% increase year-over-year.
Gossamer Bio, Inc. annual Operating Income (Loss) for 2023 was -$184M, a 15.9% increase from 2022.
Gossamer Bio, Inc. annual Operating Income (Loss) for 2022 was -$219M, a 1.14% decline from 2021.
Gossamer Bio, Inc. annual Operating Income (Loss) for 2021 was -$216M, a 7.62% increase from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	-$72.8M	-$33.9M	+$6.57M	+16.2%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-07
Q2 2024	-$79.4M	$52.1M	+$98.4M		Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-12
Q1 2024	-$178M	-$42M	+$5.98M	+12.5%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-07
Q4 2023	-$184M	-$49M	+$5.33M	+9.81%	Oct 1, 2023	Dec 31, 2023	10-K	2024-03-05
Q3 2023	-$189M	-$40.5M	+$15.5M	+27.7%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-07
Q2 2023	-$205M	-$46.3M	+$7.57M	+14.1%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-12
Q1 2023	-$212M	-$47.9M	+$6.4M	+11.8%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-07
Q4 2022	-$219M	-$54.4M	-$2.7M	-5.22%	Oct 1, 2022	Dec 31, 2022	10-K	2024-03-05
Q3 2022	-$216M	-$56M	-$357K	-0.64%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-09
Q2 2022	-$216M	-$53.9M	+$1.72M	+3.1%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-08
Q1 2022	-$217M	-$54.3M	-$1.14M	-2.14%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-09
Q4 2021	-$216M	-$51.7M	+$8.43M	+14%	Oct 1, 2021	Dec 31, 2021	10-K	2024-03-05
Q3 2021	-$225M	-$55.7M	-$2.1M	-3.91%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-03
Q2 2021	-$222M	-$55.6M	+$9.74M	+14.9%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-09
Q1 2021	-$232M	-$53.2M	+$1.76M	+3.21%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-10
Q4 2020	-$234M	-$60.1M	-$4.3M	-7.71%	Oct 1, 2020	Dec 31, 2020	10-K	2023-03-17
Q3 2020	-$230M	-$53.6M	-$3.58M	-7.17%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-08
Q2 2020	-$226M	-$65.3M	-$19M	-41%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-09
Q1 2020	-$207M	-$55M	-$21M	-61.6%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-06
Q4 2019	-$186M	-$55.8M	-$16M	-40.1%	Oct 1, 2019	Dec 31, 2019	10-K	2020-03-24
Q3 2019	-$170M	-$50M	+$38K	+0.08%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-10
Q2 2019	-$170M	-$46.3M	-$13.3M	-40.3%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-11
Q1 2019	-$157M	-$34M	-$7.89M	-30.2%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-12
Q4 2018	-$149M	-$39.8M			Oct 1, 2018	Dec 31, 2018	10-K	2020-03-24
Q3 2018		-$50M			Jul 1, 2018	Sep 30, 2018	10-K	2020-03-24
Q2 2018		-$33M			Apr 1, 2018	Jun 30, 2018	10-K	2020-03-24
Q1 2018		-$26.1M			Jan 1, 2018	Mar 31, 2018	10-K	2020-03-24

* An asterisk sign (*) next to the value indicates that the value is likely invalid.